Azaturas 25 mg/mL Injection
PDF Leaflet Revision Date: 29 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Dosage (summary)
75 mg/mu00b2 daily for 7 days, followed by 21 days rest; minimum of 6 cycles.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; potential fetal harm.
Contraindications
- Hypersensitivity to azacitidine
- Malignant hepatic tumours
- Pregnancy
- Breastfeeding
- Live vaccines
Common side effects
- Nausea
- Vomiting
- Diarrhoea
- Anaemia
- Thrombocytopenia
Counselling Points
- Monitor for signs of bleeding
- Report febrile episodes
- Use effective contraception during treatment
Serious warnings
- Haematological toxicity
- Necrotising fasciitis
- Differentiation syndrome
Important Disclaimer
The Azaturas 25 mg/mL Injection professional information leaflet below is the property of Pharma-Q Holdings and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
